

Carmel is a worldwide leader in closed drug transfer systems for handling medications. Carmel´s proprietary PhaSeal system, considered to be the gold standard in safe handling, is a unique safety solution designed to protect health care workers, patients, the drug and the hospital´s P&L.
“Carmel Pharma has achieved excellent growth over the last five years, driven by an exceptional product, a first class team of employees and very supportive shareholders," Dan Pitulia, CEO of Carmel, said. "I believe BD will be an excellent owner and it has all the capabilities to accelerate Carmel Pharma´s next phase of growth. We will benefit hugely from BD´s access to new customers and from the fact that PhaSeal is complementary to BD´s existing product range."
Read press release in English.
A win-win concept: increased safety for staff reduces costs for cytostatic agents
Read article about Carmel Pharma in Nordic Life Science Review, Q2, 2011
CYTO365 and Velit Biologics on top at regional Venture Cup final
2012-05-16
Focus on cancer treatments — a safe valve for chemotherapy treatment and a new cancer drug that chokes tumours win awards at the Venture Cup West regional final
Promimic obtains approved US patent for nano coating for implants
Näringsutskottet håller en öppen utfrågning om life science-industrins framtid i Sverige
Isofol Medical receives approval to conduct study
Vacant positions within the biotech and life science area in the Göteborg region.
Here you find a list of current calls for proposals and applications for Life Science!